Integration of Chinese herbal medicine therapy improves survival of patients with chronic lymphocytic leukemia

Medicine (United States)

Volumn 95, Issue 21, 2016, Pages

  Fleischer, Tom ^a   Chang, Tung Ti ^b,c   Chiang, Jen Huai ^b,c   Hsieh, Ching Yun ^b   Sun, Mao Feng ^b,c   Yen, Hung Rong ^b,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; ANTINEOPLASTIC AGENT; HERBACEOUS AGENT;

ACUPUNCTURE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHINESE MEDICINE; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERBAL MEDICINE; HUMAN; HYPERTENSION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TAIWAN; ADOLESCENT; COMORBIDITY; DEMOGRAPHY; EPIDEMIOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COMORBIDITY; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RESIDENCE CHARACTERISTICS; TAIWAN; YOUNG ADULT;

EID: 84973481050     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003788     Document Type: Article

References (35)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052-1057.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164-1174.
3. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-223.
4. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997-1007.
5. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48-58.
6. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-Arm, phase 2 study. Lancet Oncol. 2014;15:1090-1099.
7. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509-1518.
8. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202-208.
9. Battle TE, Castro-Malaspina H, Gribben JG, et al. Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis. Leukemia Res. 2003;27:859-863.
10. Ghosh AK, Kay NE, Secreto CR, et al. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res. 2009;15:1250-1258.
11. Lin CC, Kuo CL, Lee MH, et al. Extract of Hedyotis diffusa Willd influences murine leukemia WEHI-3 cells in vivo as well as promoting T-And B-cell proliferation in leukemic mice. In Vivo. 2011;25:633-640.
12. Nam S, Buettner R, Turkson J, et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA. 2005;102:5998-6003.
13. Radwan FF, Hossain A, God JM, et al. Reduction of myeloidderived suppressor cells and lymphoma growth by a natural triterpenoid. J Cell Biochem. 2015;116:102-114.
14. Yang G, Li X, Li X, et al. Traditional Chinese medicine in cancer care: a review of case series published in the Chinese literature. Evid Based Complement Alternat Med. 2012;2012:751046.
15. Yin CS, Ko SG. Introduction to the history and current status of evidence-based korean medicine: a unique integrated system of allopathic and holistic medicine. Evid Based Complement Alternat Med. 2014;2014:740515.
16. Huang TP, Liu PH, Lien AS, et al. A nationwide population-based study of traditional Chinese medicine usage in children in Taiwan. Complement Ther Med. 2014;22:500-510.
17. Chen FP, Chen TJ, Kung YY, et al. Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv Res. 2007;7:26.
18. NHIA, 2015. National Health Insurance Annual Report 2015-2016. National Health Insurance Administration, Ministry of Health and Welfare, Taiwan, R.O.C., Taipei.
19. Lee AL, Chen BC, Mou CH, et al. Association of traditional Chinese medicine therapy and the risk of vascular complications in patients with type II diabetes mellitus: a nationwide, retrospective, Taiwanese-registry, cohort study. Medicine. 2016;95:e2536.
20. Chang CC, Lee YC, Lin CC, et al. Characteristics of traditional Chinese medicine usage in patients with stroke in Taiwan: a nationwide population-based study. J Ethnopharmacol. 2016;186:311-321.
21. Fleischer T, Chang TT, Chiang JH, et al. Adjunctive Chinese Herbal Medicine therapy improves survival of patients with chronic myeloid leukemia: a nationwide population-based cohort study. Cancer Med. 2016;5:640-648.
22. Huang MC, Pai FT, Lin CC, et al. Characteristics of traditional Chinese medicine use in patients with rheumatoid arthritis in Taiwan: a nationwide population-based study. J Ethnopharmacol. 2015;176:9-16.
23. Wu SJ, Huang SY, Lin CT, et al. The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. Blood. 2010;116:4430-4435.
24. D'Arena G, Laurenti L, Coscia M, et al. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. Leuk Lymphoma. 2014;55:841-847.
25. Hensel M, Zoz M, Ho AD. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. Support Care Cancer. 2009;17:47-52.
26. Bucker B, Groenewold M, Schoefer Y, et al. The use of complementary alternative medicine (CAM) in 1 001 German adults: results of a population-based telephone survey. Gesundheitswesen. 2008;70:e29-e36.
27. Posadzki P, Alotaibi A, Ernst E. Prevalence of use of complementary and alternative medicine (CAM) by physicians in the UK: a systematic review of surveys. Clin Med. 2012;12:505-512.
28. Shanafelt T. Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematology Am Soc Hematol Educ Program. 2013;2013:158-167.
29. A2011 Life expectancy tables, Taiwanese Ministry of the Interior. http://sowf.moi.gov.tw/stat/english/elife/elist.htm. Accessed Aug 19, 2015.
30. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49:49-56.
31. Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99:1095-1100.
32. Nabhan C, Aschebrook-Kilfoy B, Chiu BC, et al. The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive surveillance, epidemiology, and end results analysis in the modern era. Leuk lymphoma. 2014;55:2778-2784.
33. Wu SJ, Chiang CJ, Lin CT, et al. Improving but inferior survival in patients with chronic lymphocytic leukemia in Taiwan: a populationbased study, 1990-2004. PloS One. 2013;8:e62930.
34. Gunawardana C, Austen B, Powell JE, et al. South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to White patients. Brit J Haematol. 2008;142: 606-609.
35. Leischik R, Dworrak B, Strauss M, et al. Plasticity of health. German J Med. 2016;1:1-17.